PITTSBURGH, Oct. 1 /PRNewswire/ — Mylan Inc. (Nasdaq:
MYL) today announced that its subsidiary Mylan Pharmaceuticals
Inc. has launched Bupropion Hydrochloride Extended-release Tablets
USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of
GlaxoSmithKline’s antidepressant Wellbutrin XL®.
Bupropion Hydrochloride Extended-release Tablets had U.S. sales
of approximately $752 million for the 12 months ending June 30,
2010, according to IMS Health.
Currently, Mylan has 150 ANDAs pending FDA approval representing
$94.2 billion in annual sales, according to IMS Health. Forty-two
of these pending ANDAs are potential first-to-file opportunities,
representing $21.9 billion in annual brand sales, for the 12 months
ending June 30, 2010, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty
pharmaceutical companies in the world and provides products to
customers in more than 140 countries and territories. The company
maintains one of the industry’s broadest and highest quality
product portfolios supported by a robust product pipeline; operates
one of the world’s largest active pharmaceutical ingredient
manufacturers; and runs a specialty business focused on
respiratory, allergy and psychiatric therapies. For more
information, please visit www.mylan.com.